Trials & Filings

Tesaro Begins Dose-Finding Study

Test rolapitant doses for CINV

Tesaro, Inc. has initiated an open label, dose-finding and escalation study to evaluate the pharmacokinetics, safety and tolerability of an intravenous (IV) formulation of rolapitant in healthy volunteers. Rolapitant is an investigational neurokinin-1 (NK-1) receptor antagonist in development for the prevention of chemotherapy-induced nausea and vomiting (CINV). Data from this Phase I study will be used to select the intravenous dose that will be advanced into a subsequent clinical study.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters